Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.02 | 1.56 | 0.21 |
| FCF Yield | -75.44% | -130.09% | -32.17% | -18.28% |
| EV / EBITDA | -1.11 | -0.93 | -2.65 | -5.42 |
| Quality | ||||
| ROIC | 177.25% | 717.26% | -2,302.60% | -100.48% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.78 | 1.19 | 0.80 | 1.07 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 55.59% | -5.82% | 27.25% | 25.23% |
| Safety | ||||
| Net Debt / EBITDA | -0.05 | 0.00 | -0.14 | 0.57 |
| Interest Coverage | -151.86 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -9,219.58 | -6,823.43 | -7,971.09 | -5,194.23 |